Clear Cell Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: CLR003 MIFTS: 49	Clear Cell Adenocarcinoma Categories: Cancer diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Clear Cell Adenocarcinoma

MalaCards integrated aliases for Clear Cell Adenocarcinoma:

Name: Clear Cell Adenocarcinoma ¹¹ ¹⁴ ¹⁶

Mesonephroma ¹¹ ⁴³ ⁷¹

Water-Clear Cell Adenocarcinoma ¹¹ ⁷¹

Adenocarcinoma, Clear Cell ⁴³ ⁷¹

Mesonephroid Clear Cell Carcinoma ¹¹

Water-Clear Cell Carcinoma ¹¹

Adenocarcinoma Clear Cell ⁵³

Clear-Cell Adenocarcinoma ⁷⁵

Mesonephroma, Malignant ¹¹

Malignant Mesonephroma ¹¹

Wolffian Duct Neoplasm ¹¹

Mesonephric Tumor ⁷¹

Classifications:

MalaCards categories:
Global: Cancer diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:4468

MeSH ⁴³ D008649 D018262

NCIt ⁴⁹ C36815 C4072 C4156

SNOMED-CT ⁶⁸ 2221008 30546008 80727009

EFO ¹⁶ EFO_0000348

UMLS ⁷¹ C0025490 C0206681 C0334322 more

Sources

Summaries for Clear Cell Adenocarcinoma

Disease Ontology: ¹¹ An adenocarcinoma that derives from epithelial cells which have clear cytoplasm.

MalaCards based summary: Clear Cell Adenocarcinoma, also known as mesonephroma, is related to urethra clear cell adenocarcinoma and ovarian clear cell adenocarcinoma. An important gene associated with Clear Cell Adenocarcinoma is MUC16 (Mucin 16, Cell Surface Associated), and among its related pathways/superpathways are Toll-like receptor signaling pathway and Endometrial cancer. The drugs Lenograstim and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include ovary, cervix and lymph node, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Decreased viability in pancreas lineage

Wikipedia: ⁷⁵ Clear-cell adenocarcinoma is a type of adenocarcinoma that shows clear... more...

Sources

Related Diseases for Clear Cell Adenocarcinoma

Diseases related to Clear Cell Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 407)

#	Related Disease	Score	Top Affiliating Genes
1	urethra clear cell adenocarcinoma	33.0	PAX8 KRT7
2	ovarian clear cell adenocarcinoma	32.4	TP53 HNF1B ARID1A
3	endometrial clear cell adenocarcinoma	32.4	NAPSA HNF1B
4	cervical clear cell adenocarcinoma	32.3	NAPSA KRT7
5	wolffian duct adenoma	32.1	PAX8 MME KRT7 KLK3
6	bladder clear cell adenocarcinoma	31.6	TP53 PAX8 NAPSA MME KRT7
7	urethra adenocarcinoma	31.3	PAX8 KRT7
8	cervical adenocarcinoma	30.9	TP53 MUC16 KRT7 IFI27
9	appendix adenocarcinoma	30.9	TP53 SMAD4 KRT7
10	endometrial adenocarcinoma	30.7	TP53 PAX8 KRT7
11	endodermal sinus tumor	30.6	MUC16 KRT7 KLK3 ACP3
12	adenoma	30.5	TP53 SMAD4 SMAD3 KRT7 CCND1
13	adenocarcinoma	30.5	TP53 SMAD4 SMAD3 SMAD2 NAPSA KRT7
14	ovary adenocarcinoma	30.5	TP53 PAX8 MUC16 KRT7 INHBA ARID1A
15	urethral diverticulum	30.5	PAX8 NAPSA KRT7 KLK3
16	clear cell adenofibroma	30.4	NAPSA ARID1A
17	collecting duct carcinoma	30.4	PAX8 MME KRT7
18	vaginal cancer	30.4	TP53 MME KRT7
19	suppression of tumorigenicity 12	30.2	TP53 SMAD4 KLK3
20	bladder adenocarcinoma	30.2	TP53 NAPSA KRT7 KLK3
21	colon adenocarcinoma	30.2	TP53 SMAD4 SMAD3 SMAD2 CCND1 ARID1A
22	transitional cell carcinoma	30.1	TP53 MUC16 KRT7 KLK3
23	polycystic liver disease 1 with or without kidney cysts	30.1	MUC16 KRT7 HNF1B
24	male urethral cancer	30.0	TP53 KRT7 KLK3
25	urinary tract obstruction	30.0	SMAD3 SMAD2 KRT7 KLK3
26	nephrogenic adenoma	30.0	PAX8 NAPSA MME KRT7 KLK3
27	pancreatic adenocarcinoma	30.0	TP53 SMAD4 SMAD2 CCND1
28	colorectal adenoma	30.0	TP53 SMAD4 CCND1
29	hydronephrosis	30.0	MME KRT7 KLK3
30	small-cell carcinoma of the ovary of hypercalcemic type	30.0	TP53 ARID1A
31	mucinous adenocarcinoma	30.0	TP53 SMAD4 PAX8 NAPSA KRT7
32	vulva cancer	29.9	TP53 KRT7 CCND1
33	endosalpingiosis	29.9	TP53 PAX8 KRT7
34	fallopian tube carcinoma	29.9	TP53 PAX8 KRT7
35	renal cell carcinoma, papillary, 1	29.9	TP53 PAX8 MME KRT7
36	squamous cell carcinoma	29.9	TP53 SMAD4 PTHLH KRT7 CCND1
37	ovarian cancer	29.9	TP53 SMAD4 SMAD3 SMAD2 MUC16 KRT7
38	cystadenocarcinoma	29.8	TP53 PAX8 MUC16 KRT7 ARID1A
39	ovarian serous cystadenocarcinoma	29.8	TP53 SMAD4 PAX8 MUC16
40	papilloma	29.8	TP53 KRT7 IFI27 CCND1
41	adenocarcinoma in situ	29.8	TP53 NAPSA KRT7
42	adrenal cortical carcinoma	29.7	TP53 SMAD4 PAX8 CCND1
43	nephrogenic adenoma of the urethra	29.7	PAX8 MME KRT7 KLK3
44	ovarian clear cell carcinoma	29.7	TP53 NAPSA HNF1B ARID1A
45	endometrial cancer	29.7	TP53 SMAD4 SMAD3 SMAD2 MUC16 MME
46	cervix carcinoma	29.7	TP53 PAX8 KRT7 CCND1
47	squamous cell carcinoma, head and neck	29.6	TP53 SMAD4 SMAD3 SMAD2 CCND1
48	urethral benign neoplasm	29.6	TP53 PAX8 MME KRT7 KLK3
49	serous cystadenocarcinoma	29.6	TP53 PAX8 NAPSA MUC16 KRT7 HNF1B
50	rhabdomyosarcoma	29.5	TP53 SMAD4 SMAD3 SMAD2 MME KRT7

Graphical network of the top 20 diseases related to Clear Cell Adenocarcinoma:

Sources

Symptoms & Phenotypes for Clear Cell Adenocarcinoma

GenomeRNAi Phenotypes related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

²⁵ (show all 19)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased shRNA abundance (Z-score > 2)	GR00366-A-100	9.62	SMAD2
2	Increased shRNA abundance (Z-score > 2)	GR00366-A-107	9.62	SMAD4
3	Increased shRNA abundance (Z-score > 2)	GR00366-A-11	9.62	SMAD2 SMAD4
4	Increased shRNA abundance (Z-score > 2)	GR00366-A-134	9.62	CCND1
5	Increased shRNA abundance (Z-score > 2)	GR00366-A-152	9.62	CCND1
6	Increased shRNA abundance (Z-score > 2)	GR00366-A-166	9.62	PAX8
7	Increased shRNA abundance (Z-score > 2)	GR00366-A-172	9.62	SMAD2
8	Increased shRNA abundance (Z-score > 2)	GR00366-A-174	9.62	SMAD2
9	Increased shRNA abundance (Z-score > 2)	GR00366-A-195	9.62	SMAD4
10	Increased shRNA abundance (Z-score > 2)	GR00366-A-203	9.62	SMAD2
11	Increased shRNA abundance (Z-score > 2)	GR00366-A-205	9.62	SMAD2
12	Increased shRNA abundance (Z-score > 2)	GR00366-A-21	9.62	CCND1
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-210	9.62	CCND1
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-211	9.62	CCND1
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-212	9.62	SMAD4
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-25	9.62	SMAD2 SMAD4
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-36	9.62	CCND1
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-43	9.62	SMAD4
19	Decreased viability in pancreas lineage	GR00235-A	9.35	ARID1A CCND1 KRT7 SMAD3 TP53

MGI Mouse Phenotypes related to Clear Cell Adenocarcinoma:

⁴⁵ (show all 11)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.25	ARID1A CCND1 HNF1B IFI27 INHBA KRT7
2	endocrine/exocrine gland	MP:0005379	10.15	ACP3 ARID1A CCND1 HNF1B INHBA PAX8
3	normal	MP:0002873	10.13	ARID1A CCND1 INHBA KLK3 PAX8 PTHLH
4	neoplasm	MP:0002006	10.1	ACP3 ARID1A CCND1 PTHLH SMAD2 SMAD3
5	renal/urinary system	MP:0005367	10.06	HNF1B INHBA KRT7 PAX8 PTHLH SMAD3
6	liver/biliary system	MP:0005370	10.03	HNF1B MME PTHLH SLC2A4 SMAD2 SMAD3
7	digestive/alimentary	MP:0005381	9.97	CCND1 HNF1B INHBA PTHLH SLC2A4 SMAD2
8	cellular	MP:0005384	9.97	ARID1A CCND1 HNF1B INHBA KRT7 MME
9	craniofacial	MP:0005382	9.91	ARID1A CCND1 INHBA PAX8 PTHLH SMAD2
10	cardiovascular system	MP:0005385	9.7	ARID1A CCND1 IFI27 KLK3 PAX8 PTHLH
11	reproductive system	MP:0005389	9.36	ACP3 ARID1A CCND1 INHBA MUC16 PAX8

Sources

Drugs & Therapeutics for Clear Cell Adenocarcinoma

Drugs for Clear Cell Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 135)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Lenograstim

Approved, Investigational

Phase 3

135968-09-1

Bevacizumab

Approved, Investigational

Phase 3

216974-75-3

135329020

Rucaparib

Approved, Investigational

Phase 3

283173-50-2

9931954

Topotecan

Approved, Investigational

Phase 2, Phase 3

123948-87-8, 119413-54-6

60699 60700

Olaparib

Approved

Phase 3

763113-22-0

23725625

Doxorubicin

Approved, Investigational

Phase 2, Phase 3

23214-92-8

31703

Gemcitabine

Approved

Phase 3

95058-81-4, 122111-03-9

60750

Docetaxel

Approved, Investigational

Phase 3

114977-28-5

148124

Cisplatin

Approved

Phase 3

15663-27-1

2767 5702198 441203

Atezolizumab

Approved, Investigational

Phase 2, Phase 3

1380723-44-3

Metformin

Approved

Phase 2, Phase 3

1115-70-4, 657-24-9

4091

Paclitaxel

Approved, Vet_approved

Phase 3

33069-62-4

36314

Carboplatin

Approved

Phase 3

41575-94-4

10339178 38904

Niraparib

Approved, Investigational

Phase 3

1038915-60-4

24958200

Glutamic acid

Approved, Nutraceutical

Phase 3

56-86-0

33032

Cediranib

Investigational

Phase 3

288383-20-0

9933475

Maleic acid

Experimental, Investigational

Phase 3

110-16-7, 110-17-8

444266 444972

Paclitaxel poliglumex

Experimental, Investigational

Phase 3

263351-82-2

Carotenoids

Phase 3

Adjuvants, Immunologic

Phase 3

Immunologic Factors

Phase 3

Angiogenesis Inhibitors

Phase 3

Anti-Bacterial Agents

Phase 2, Phase 3

topoisomerase I inhibitors

Phase 2, Phase 3

Antimitotic Agents

Phase 3

Poly(ADP-ribose) Polymerase Inhibitors

Phase 3

Tubulin Modulators

Phase 3

Antibiotics, Antitubercular

Phase 2, Phase 3

Liposomal doxorubicin

Phase 2, Phase 3

Protein Kinase Inhibitors

Phase 3

Antiviral Agents

Phase 3

Anti-Infective Agents

Phase 3

Antimetabolites

Phase 3

Immunosuppressive Agents

Phase 3

Taxane

Phase 3

108169

Hypoglycemic Agents

Phase 2, Phase 3

Albumin-Bound Paclitaxel

Phase 3

Tin Fluorides

Phase 3

Vinblastine

Approved

Phase 2

865-21-4

241903 13342

Capecitabine

Approved, Investigational

Phase 2

154361-50-9

60953

Xylometazoline

Approved, Investigational

Phase 2

526-36-3

5709

Cyclophosphamide

Approved, Investigational

Phase 2

50-18-0, 6055-19-2

2907

Sunitinib

Approved, Investigational

Phase 2

557795-19-4

5329102

Nintedanib

Approved

Phase 2

656247-17-5

135423438 9809715

Thalidomide

Approved, Investigational, Withdrawn

Phase 2

50-35-1

5426

Iodine

Approved, Investigational

Phase 2

7553-56-2

807

Ipilimumab

Approved

Phase 2

477202-00-9

Levoleucovorin

Approved, Experimental, Investigational

Phase 1, Phase 2

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Anastrozole

Approved, Investigational

Phase 2

120511-73-1

2187

Lenvatinib

Approved, Investigational

Phase 2

417716-92-8

9823820

Interventional clinical trials:

(show top 50) (show all 107)

#	Name	Status	NCT ID	Phase	Drugs
1	Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?	Unknown status	NCT00719303	Phase 3
2	A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma	Unknown status	NCT00807768	Phase 3	Carboplatin;Paclitaxel
3	A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma	Completed	NCT00951496	Phase 3	Carboplatin;Cisplatin;Paclitaxel
4	A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer	Completed	NCT00262847	Phase 3	Carboplatin;Paclitaxel
5	A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma	Completed	NCT00006011	Phase 3	Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
6	Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy	Recruiting	NCT04575935	Phase 3	Chemotherapy
7	Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients	Recruiting	NCT04227522	Phase 3	Rucaparib;Placebos
8	A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Platinum-doublet Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (OnPrime, GOG-3076)	Recruiting	NCT05281471	Phase 3	Platinum chemotherapy: carboplatin (preferred) or cisplatin;Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin;Bevacizumab (or biosimilar)
9	A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)	Active, not recruiting	NCT00565851	Phase 3	Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
10	A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer	Active, not recruiting	NCT02839707	Phase 2, Phase 3	Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
11	A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer	Active, not recruiting	NCT03914612	Phase 3	Carboplatin;Paclitaxel
12	A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy	Active, not recruiting	NCT00108745	Phase 3	Paclitaxel;Paclitaxel Poliglumex
13	A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Active, not recruiting	NCT02446600	Phase 3	Carboplatin;Cediranib Maleate;Gemcitabine;Gemcitabine Hydrochloride;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride
14	A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)	Active, not recruiting	NCT02502266	Phase 2, Phase 3	Cediranib;Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan;Topotecan Hydrochloride
15	A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer	Active, not recruiting	NCT02065687	Phase 2, Phase 3	Carboplatin;Metformin Hydrochloride;Paclitaxel
16	A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma	Active, not recruiting	NCT00942357	Phase 3	Carboplatin;Cisplatin;Paclitaxel
17	Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE)	Active, not recruiting	NCT03422198	Phase 3
18	Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel	Active, not recruiting	NCT02501954	Phase 3	Cisplatin;Carboplatin;Paclitaxel
19	A Phase III Randomized, Open Label Study of A Phase III Randomized, Open Label Study of NiraParib Maintenance After Carboplatin and Paclitaxel in optimaLly debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy (N-Plus)	Not yet recruiting	NCT05460000	Phase 3	3 cycles chemotherapy instead of 6 cycles chemotherapy;6 cycles chemotherapy
20	Interleukin-2, Interferon Alpha,Capecitabine and Vinblastin for Treatment of Metastatic Renal Cell Carcinoma: A Multicenter Study	Unknown status	NCT00226798	Phase 2	Capecitabine (Xeloda)
21	A Multicentre Phase II Randomised Trial of Durvalumab (MEDI4736) Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas (MOCCA)	Unknown status	NCT03405454	Phase 2	durvalumab;standard chemotherapy
22	A Randomised Phase II Study Of Nintedanib (BIBF1120) Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium	Unknown status	NCT02866370	Phase 2	Nintedanib;Paclitaxel;Pegylated Liposomal Doxorubicin (PLD);Topotecan;Carboplatin;Doxorubicin
23	A Phase II Trial of Bevacizumab With Carboplatin and Weekly Paclitaxel as First-Line Treatment in Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma	Completed	NCT01097746	Phase 2	Carboplatin;Paclitaxel
24	A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer	Completed	NCT00888615	Phase 2	Elesclomol Sodium;Paclitaxel
25	A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women With Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum	Completed	NCT02315430	Phase 2	Cabozantinib S-malate
26	A Phase II Evaluation of Pembrolizumab in Combination With IV Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Completed	NCT02853318	Phase 2	Cyclophosphamide
27	A Randomized Phase II Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Completed	NCT02923739	Phase 2	Paclitaxel
28	A Phase II Evaluation of Gemcitabine (Gemzar®, LY188011) in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Completed	NCT00820898	Phase 2	Gemcitabine Hydrochloride
29	A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer	Completed	NCT01005329	Phase 2	Carboplatin;Cisplatin;Paclitaxel
30	A Phase II Evaluation of Brivanib (BMS582664), an Oral, Multitargeted Growth Factor Tyrosine Kinase Inhibitor in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Completed	NCT00888173	Phase 2	Brivanib Alaninate
31	A Phase II Evaluation of AZD6244 (NSC #748727) in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Completed	NCT01011933	Phase 2	Selumetinib
32	A Phase II Evaluation of Cediranib (Recentin; AZD2171, IND#72740, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Completed	NCT01132820	Phase 2	Cediranib Maleate
33	A Phase II Evaluation of SU11248 (Sunitinib Malate) (NSC #736511) in the Treatment of Persistent or Recurrent Clear Cell Ovarian Carcinoma	Completed	NCT00979992	Phase 2	Sunitinib Malate
34	A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Completed	NCT01642082	Phase 2
35	A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Completed	NCT01225887	Phase 2	Nintedanib
36	A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium	Completed	NCT01210222	Phase 2
37	A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer	Completed	NCT01307631	Phase 2	Akt Inhibitor MK2206
38	Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas	Completed	NCT01914510	Phase 2	ENMD-2076
39	Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 OR 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage	Completed	NCT00416455	Phase 1, Phase 2	ferumoxtran-10
40	A Phase II Study of CCI-779 in Patients With Metastatic and/or Locally Advanced Recurrent Endometrial Cancer	Completed	NCT00072176	Phase 2	temsirolimus
41	A Phase II Evaluation of Thalidomide (NSC #66847, IND 48832) in the Treatment of Recurrent of Persistent Endometrial Carcinoma	Completed	NCT00025467	Phase 2	thalidomide
42	Evaluation of the Efficacy of Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma	Completed	NCT01824615	Phase 2	Sunitinib
43	A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab	Recruiting	NCT04739800	Phase 2	Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
44	MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer	Recruiting	NCT02364713	Phase 2	Gemcitabine Hydrochloride;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
45	EON: A Single-Arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer	Recruiting	NCT05026606	Phase 2
46	Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer	Recruiting	NCT02068794	Phase 1, Phase 2
47	A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)	Recruiting	NCT03866382	Phase 2	Cabozantinib S-malate
48	A Phase II Clinical Trial Evaluating the Combination of Onapristone With Anastrozole for Women With Refractory Hormone Receptor Positive Endometrial Cancer	Recruiting	NCT04719273	Phase 2	Extended-release Onapristone;Anastrozole
49	BrUOG 354: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas	Recruiting	NCT03355976	Phase 2	Nivolumab;Ipilimumab
50	A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial Carcinoma	Recruiting	NCT05112601	Phase 2

Search NIH Clinical Center for Clear Cell Adenocarcinoma

Cochrane evidence based reviews: mesonephroma

Sources

Genetic Tests for Clear Cell Adenocarcinoma

Sources

Anatomical Context for Clear Cell Adenocarcinoma

Organs/tissues related to Clear Cell Adenocarcinoma:

MalaCards : Ovary, Cervix, Lymph Node, Uterus, Prostate, Kidney, T Cells

Sources

Publications for Clear Cell Adenocarcinoma

Articles related to Clear Cell Adenocarcinoma:

(show top 50) (show all 1060)

#	Title	Authors	PMID	Year
1	Expression of glucose transporters in epithelial ovarian carcinoma: correlation with clinical characteristics and tumor angiogenesis. ⁵³ ⁶²	Tsukioka M...Ishiko O	17611657	2007
2	MMAC tumor supressor gene expression in ovarian endometriosis and ovarian adenocarcinoma. ⁵³ ⁶²	Cirpan T...Sagol S	17713092	2007
3	The autocrine effect of activin A on human ovarian clear cell adenocarcinoma cells. ⁵³ ⁶²	Mabuchi Y...Umesaki N	16820918	2006
4	PTEN expression in clear cell adenocarcinoma of the ovary. ⁵³ ⁶²	Hashiguchi Y...Mok SC	16290000	2006
5	Clear cell adenocarcinoma of the female urethra showing strong immunostaining for prostate-specific antigen. ⁵³ ⁶²	Kawano K...Yasuda K	11251541	2001
6	Hypercalcemia due to parathyroid hormone-related protein produced by primary ovarian clear cell adenocarcinoma: case report. ⁵³ ⁶²	Tsunematsu R...Tsukamoto N	10637074	2000
7	Clear cell adenocarcinoma and nephrogenic adenoma of the urethra and urinary bladder: a histopathologic and immunohistochemical comparison. ⁵³ ⁶²	Gilcrease MZ...Albores-Saavedra J	9865832	1998
8	Ovarian vein vs peripheral blood CA125 serum levels: a comparative study. ⁵³ ⁶²	Podnos YD...Manetta A	9234924	1997
9	[A case of clear cell adenocarcinoma of the female urethra]. ⁵³ ⁶²	Miyai M...Ebisuno S	7645457	1995
10	Clear cell adenocarcinoma of the female urethra showing positive staining with antibodies to prostate-specific antigen and prostatic acid phosphatase. ⁵³ ⁶²	Ebisuno S...Nagareda T	7536368	1995
11	Nephrogenic adenoma of the prostatic urethra involving the prostate gland: a clinicopathologic and immunohistochemical study of eight cases. ⁵³ ⁶²	Malpica A...Ayala AG	7512941	1994
12	Synchronous primary malignancies in ovarian cancer and liver angiosarcoma. ⁶²	Taguchi T...Ito K	36217325	2022
13	GATA3 expression in clear cell adenocarcinoma of the lower urinary tract: a potential diagnostic pitfall. ⁶²	Akgul M...Mohanty SK	36320040	2022
14	Female urethral carcinoma: a contemporary review of the clinicopathologic features, with emphasis on the histoanatomic landmarks and potential staging issues. ⁶²	Lagarde-Lenon MS...Aron M	36037997	2022
15	Postmenopausal Vaginal and Cervical Cancer Risk Related to In Utero Diethylstilbestrol Exposure. ⁶²	Wamakima BW...Farid H	36222810	2022
16	Primary clear cell adenocarcinoma of the vagina not associated with diethylstilbestrol: A case report. ⁶²	Haddout S...El Karroumi M	35987029	2022
17	Radical trachelectomy and adjuvant vaginal brachytherapy to preserve fertility in pediatric cervical adenocarcinoma. ⁶²	Hutten RJ...Burt LM	35973904	2022
18	Nephrogenic Adenoma Intermixed With Urothelial Carcinoma. ⁶²	Kryvenko ON...Williamson SR	35976666	2022
19	Risk of clear-cell adenocarcinoma of the vagina and cervix among US women with potential exposure to diethylstilbestrol in utero. ⁶²	White MC...Thompson TD	35767133	2022
20	Implementation of Image-Guided Brachytherapy for Pediatric Vaginal Cancers: Feasibility and Early Clinical Results. ⁶²	Terlizzi M...Chargari C	35805018	2022
21	Diagnosis of Lung Adenocarcinoma with Clear Cell Features in Pleural Effusion: Cytomorphologic Features, Immunocytochemical Studies, and Differential Diagnosis. ⁶²	Erdogan-Durmus S...Erdem ZB	36277803	2022
22	Laparoscopic posterior pelvic exenteration for clear cell adenocarcinoma arising in an episiotomy scar. ⁶²	Kasahara K...Obama K	35086165	2022
23	Primary clear cell adenocarcinoma of female urinary tract: a case report and literature review. ⁶²	Miao J...Li J	35751118	2022
24	Clear cell adenocarcinoma arising from anterior abdominal wall cesarean section scar endometriosis treated with excision and the addition of Trastuzumab for adjuvant chemotherapy: A case report. ⁶²	Lewis GK...Robertson MW	35574241	2022
25	Renal metastasis of ovarian granulosa cell tumor. ⁶²	Togashi K...Ohyama C	35509773	2022
26	[Clinical analysis of 23 cases with simultaneous double primary gynecological malignant tumors]. ⁶²	He Y...Wu YM	35658326	2022
27	Vesical clear cell adenocarcinoma of Müllerian origin treated conservatively with partial cystectomy. ⁶²	Harold JA...Ratner ES	35383096	2022
28	[Spontaneous rupture of kidney tumor. Successful surgical treatment]. ⁶²	Neymark AI...Davydov AV	35274864	2022
29	Cervical cytology in the detection of uterine clear cell carcinoma: Diagnostic predictors from a case-control study. ⁶²	Gupta P...Suri V	34619807	2022
30	Clear Cell Adenocarcinoma In Situ as a Potential Precursor Lesion for Sporadic Invasive Endocervical Clear Cell Adenocarcinoma. ⁶²	Stolnicu S...Soslow RA	35283444	2022
31	Pathological examination of a placenta leading to the diagnosis of endometrial carcinoma: A case report. ⁶²	Maeda T...Iwasa T	34909202	2022
32	Recent Trends in the Incidence of Clear Cell Adenocarcinoma and Survival Outcomes: A SEER Analysis. ⁶²	Guo Y...Yao X	35282450	2022
33	Factors Associated with Patient Survival in Clear Cell Adenocarcinoma of the Cervix: A Single-Center Experience in China. ⁶²	Wang T...Hua K	35535144	2022
34	Successful treatment of a 19-year-old patient with locally advanced clear cell adenocarcinoma of the uterine cervix using recombinant human adenovirus type 5 (Oncorine) combined with chemoradiotherapy: a case report. ⁶²	Zhang J...Gong TT	35071441	2021
35	Distinct mutational status in GATA3-Positive clear cell adenocarcinoma of the urinary tract: A CASE report. ⁶²	Abdelwahab H...Akgul M	34401347	2021
36	Primary clear cell adenocarcinoma of prostate: A diagnostic challenge. ⁶²	Chang CW...Li CC	34759659	2021
37	Female Urethral Clear Cell Adenocarcinoma: A Case Report. ⁶²	Mazuecos Quiros J...Medina Lopez RA	34175333	2021
38	[Clear cell adenocarcinoma in the prostate:report of a case]. ⁶²	Liu W...Liu L	34496508	2021
39	Screening for cancers of the cervix and vagina for women exposed to diethylstilbestrol (DES) in utero. ⁶²	Tournaire M...Levadou A	33310134	2021
40	Immunochemical analysis of iron transporters and M2 macrophages in ovarian endometrioma and clear cell adenocarcinoma. ⁶²	Akashi K...Oda H	34194738	2021
41	A Rare Case of Clear Cell Cervical Carcinoma to a Woman, 50 Years After Diethylstilbestrol Exposure for Lactation Suppression. ⁶²	Palaiologos K...Flynn M	34589362	2021
42	Uncommon Cervical Lesions: A Review and Discussion of the Differential Diagnosis. ⁶²	Griesinger LM...Skala SL	33091926	2021
43	Primary Clear Cell Carcinoma of the Pancreas: A Systematic Review. ⁶²	Tannous T...Keating M	34150416	2021
44	Clear cell carcinoma of the urinary bladder: a systematic review. ⁶²	Chan EO...Teoh JY	33462714	2021
45	Intensity-modulated radiotherapy combined with intracavitary brachytherapy for locally advanced cervical cancer with uterus didelphys. ⁶²	Lei C...Xu Y	33718560	2021
46	Plasma cell neoplasms of the bladder: a series of 9 cases. ⁶²	Gupta R...Epstein JI	33639141	2021
47	Metastases from renal cell carcinoma-Report of three unpredictable cases and literature review. ⁶²	Malhotra KP...Malhotra HS	34100413	2021
48	Early stage clear cell adenocarcinoma coexisting with tubular adenoma and adenoma with clear cell change in the colon. ⁶²	Tochio T...Kushima R	33420668	2021
49	Clear-Cell Adenocarcinoma of the Gallbladder with Alpha-Fetoprotein Production: A Case Report and Review of the Literature. ⁶²	Dixit N...Bansal VK	33981682	2021
50	Mesonephric (Wolffian-derived) Adenocarcinoma of the Female Urethra. ⁶²	Paner GP...Amin MB	33284194	2021

Sources

Genes for Clear Cell Adenocarcinoma

Genes related to Clear Cell Adenocarcinoma (0 elite genes):

(show all 21)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	MUC16	Mucin 16, Cell Surface Associated	Protein Coding	19.24	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9234924 17713092
2	KLK3	Kallikrein Related Peptidase 3	Protein Coding	16.79	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	7536368 9865832 7645457 (more) 11251541 7512941
3	ACP3	Acid Phosphatase 3	Protein Coding	15.41	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	7536368 9865832 7645457
4	SMAD4	SMAD Family Member 4	Protein Coding	15.39	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16820918
5	SMAD3	SMAD Family Member 3	Protein Coding	15.33	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16820918
6	SMAD2	SMAD Family Member 2	Protein Coding	11.88	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16820918
7	SLC22A16	Solute Carrier Family 22 Member 16	Protein Coding	11.04	DISEASES inferred ¹⁴ GeneCards inferred via : Expressions (show sections)
8	IFI27	Interferon Alpha Inducible Protein 27	Protein Coding	10.91	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16290000
9	CCND1	Cyclin D1	Protein Coding	10.32	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
10	INHBA	Inhibin Subunit Beta A	Protein Coding	10.17	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
11	PTHLH	Parathyroid Hormone Like Hormone	Protein Coding	7.22	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10637074
12	KRT7	Keratin 7	Protein Coding	6.68	DISEASES inferred ¹⁴
13	SLC2A4	Solute Carrier Family 2 Member 4	Protein Coding	6.53	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15907336 17611657
14	PAX8	Paired Box 8	Protein Coding	6.36	DISEASES inferred ¹⁴
15	HNF1B	HNF1 Homeobox B	Protein Coding	6.26	DISEASES inferred ¹⁴
16	ARID1A	AT-Rich Interaction Domain 1A	Protein Coding	6.13	DISEASES inferred ¹⁴
17	TP53	Tumor Protein P53	Protein Coding	6.02	DISEASES inferred ¹⁴
18	MME	Membrane Metalloendopeptidase	Protein Coding	5.96	DISEASES inferred ¹⁴
19	CCDC54	Coiled-Coil Domain Containing 54	Protein Coding	5.81	DISEASES inferred ¹⁴
20	NAPSA	Napsin A Aspartic Peptidase	Protein Coding	5.8	DISEASES inferred ¹⁴
21	PAX2	Paired Box 2	Protein Coding	5.74	DISEASES inferred ¹⁴

Sources

Variations for Clear Cell Adenocarcinoma

Copy number variations for Clear Cell Adenocarcinoma from CNVD:

⁶

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	218693	7	116312458	116438439	Amplification	MET	Clear cell adenocarcinoma
2	266962	Y	174481503	174538309	Duplication	AZF1	Clear cell adenocarcinoma

Sources

Expression for Clear Cell Adenocarcinoma

Search GEO for disease gene expression data for Clear Cell Adenocarcinoma.

Sources

Pathways for Clear Cell Adenocarcinoma

Pathways related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 40)

#	Super pathways	Score	Top Affiliating Genes
1	Toll-like receptor signaling pathway ⁷⁴ Show member pathways Hepatitis B infection ⁷⁴ Measles virus infection ⁷⁴ Regulation of toll-like receptor signaling pathway ⁷⁴	12.79	TP53 SMAD4 SMAD3 SMAD2 CCND1
2	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.65	TP53 SMAD4 SMAD3 SMAD2 CCND1
3	Human Embryonic Stem Cell Pluripotency ⁶⁴ Show member pathways Factors Promoting Cardiogenesis in Vertebrates ⁶⁴	12.42	SMAD4 SMAD3 SMAD2 HNF1B
4	Signaling by TGFB family members ⁶⁶ Show member pathways Antagonism of Activin by Follistatin ⁶⁶ Signaling by Activin ⁶⁶ Signaling by TGF-beta Receptor Complex ⁶⁶ TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) ⁶⁶	12.36	SMAD4 SMAD3 SMAD2 INHBA
5	Cell cycle Regulation of G1/S transition (part 1) ²² Show member pathways Cell cycle ESR1 regulation of G1/S transition ²² Cell cycle Role of SCF complex in cell cycle regulation ²² Immune response MIF-JAB1 signaling ²² Mitotic Roles of Polo Like Kinases ⁶⁴	12.3	SMAD4 SMAD3 SMAD2 CCND1
6	Epithelial to mesenchymal transition in colorectal cancer ⁷⁴	12.11	TP53 SMAD4 SMAD3 SMAD2
7	Cell cycle ⁷⁴ Show member pathways G1 to S cell cycle control ⁷⁴	12.1	TP53 SMAD4 SMAD3 SMAD2 CCND1
8	Integrated breast cancer pathway ⁷⁴	12.08	TP53 SMAD4 SMAD2 CCND1
9	Colorectal Cancer Metastasis ⁶⁴	11.94	TP53 SMAD4 SMAD3 SMAD2 CCND1
10	TGF-beta receptor signaling in skeletal dysplasias ⁷⁴ Show member pathways TGF-beta receptor signaling ⁷⁴	11.92	SMAD4 SMAD3 SMAD2 INHBA
11	Senescence and autophagy in cancer ⁷⁴	11.86	TP53 SMAD4 SMAD3 INHBA
12	TGF-beta receptor signaling activates SMADs ⁶⁶ Show member pathways Downregulation of TGF-beta receptor signaling ⁶⁶ Loss of Function of SMAD2/3 in Cancer ⁶⁶ Loss of Function of TGFBR1 in Cancer ⁶⁶ Signaling by TGF-beta Receptor Complex in Cancer ⁶⁶ TGF-beta signaling pathway ⁷⁴ TGFBR1 LBD Mutants in Cancer ⁶⁶	11.85	SMAD4 SMAD3 SMAD2
13	TGF-beta Signaling Pathways ⁶⁵	11.84	SMAD4 SMAD3 SMAD2
14	Cytokine production by Th17 cells in CF (Mouse model) ²² Show member pathways Cytokine production by Th17 cells in CF ²²	11.82	SMAD4 SMAD3 SMAD2
15	DNA damage response (only ATM dependent) ⁷⁴	11.82	TP53 SMAD4 SMAD3 CCND1
16	Th17 Differentiation ⁶⁵ Show member pathways IL-21 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵	11.8	SMAD4 SMAD3 SMAD2
17	Overlap between signal transduction pathways contributing to LMNA laminopathies ⁷⁴ Show member pathways Influence of laminopathies on Wnt signaling ⁷⁴	11.75	CCND1 SLC2A4 SMAD2 SMAD3
18	Validated targets of C-MYC transcriptional activation ⁶¹	11.74	TP53 SMAD4 SMAD3
19	Mesodermal commitment pathway ⁷⁴	11.72	SMAD4 SMAD3 SMAD2 INHBA CCND1
20	Burn wound healing ⁷⁴	11.71	TP53 SMAD3 INHBA
21	Regulation of nuclear SMAD2/3 signaling ⁶¹	11.7	SMAD4 SMAD3 SMAD2
22	Head and neck squamous cell carcinoma ⁷⁴	11.69	CCND1 SMAD4 TP53
23	Development_TGF-beta receptor signaling ²²	11.67	SMAD4 SMAD3 SMAD2
24	Transcription_P53 signaling pathway ²²	11.65	TP53 SMAD4 SMAD3 SMAD2
25	Validated targets of C-MYC transcriptional repression ⁶¹	11.6	SMAD4 SMAD2 CCND1
26	IL-2 Gene Expression in Activated and Quiescent T-Cells ⁶⁴ Show member pathways TOB in T-Cell Signaling ⁶⁴	11.56	SMAD4 SMAD3 SMAD2 CCND1
27	NRP1-triggered signaling pathways in pancreatic cancer ⁷⁴	11.52	SMAD4 SMAD3 SMAD2
28	TGF-beta receptor signaling ⁶¹	11.49	SMAD4 SMAD3 SMAD2
29	Integrated cancer pathway ⁷⁴	11.35	SMAD2 SMAD3 TP53
30	Envelope proteins and their potential roles in EDMD physiopathology ⁷⁴	11.32	SMAD4 SMAD3 SMAD2
31	Hepatitis C and hepatocellular carcinoma ⁷⁴	11.3	TP53 SMAD4 SMAD3 CCND1
32	Signaling by NODAL ⁶⁶ Show member pathways Regulation of signaling by NODAL ⁶⁶	11.27	SMAD4 SMAD3 SMAD2
33	Extracellular vesicle-mediated signaling in recipient cells ⁷⁴	11.17	SMAD4 SMAD3 SMAD2
34	Hypothesized pathways in pathogenesis of cardiovascular disease ⁷⁴	11.1	SMAD4 SMAD3 SMAD2
35	Progeria-associated lipodystrophy ⁷⁴ Show member pathways Lamin A-processing pathway ⁷⁴	11.01	SMAD4 SMAD3 SMAD2
36	Endoderm differentiation ⁷⁴	10.87	SMAD4 SMAD3 SMAD2 PTHLH HNF1B
37	Canonical and non-canonical TGF-B signaling ⁷⁴	10.86	SMAD4 SMAD3 SMAD2
38	TGF-beta signaling in thyroid cells for epithelial-mesenchymal transition ⁷⁴	10.73	SMAD4 SMAD3 SMAD2
39	Regulation of cytoplasmic and nuclear SMAD2/3 signaling ⁶¹	10.66	SMAD4 SMAD3 SMAD2
40	SMAD2/3 MH2 Domain Mutants in Cancer ⁶⁶ Show member pathways Loss of Function of SMAD4 in Cancer ⁶⁶ SMAD4 MH2 Domain Mutants in Cancer ⁶⁶	10.09	SMAD4 SMAD3 SMAD2

Sources

GO Terms for Clear Cell Adenocarcinoma

Cellular components related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	transcription regulator complex	GO:0005667	9.96	TP53 SMAD4 SMAD3 SMAD2 HNF1B
2	activin responsive factor complex	GO:0032444	9.46	SMAD4 SMAD2
3	heteromeric SMAD protein complex	GO:0071144	9.43	SMAD4 SMAD3 SMAD2
4	SMAD protein complex	GO:0071141	9.1	SMAD4 SMAD3 SMAD2

Biological processes related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 25)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of cell population proliferation	GO:0008285	10.34	TP53 SMAD4 SMAD3 SMAD2 PTHLH INHBA
2	positive regulation of DNA-templated transcription	GO:0045893	10.31	TP53 SMAD4 SMAD3 SMAD2 PAX8 INHBA
3	anatomical structure morphogenesis	GO:0009653	10.21	PAX8 SMAD2 SMAD3 SMAD4
4	negative regulation of cell growth	GO:0030308	10.18	INHBA SMAD3 SMAD4 TP53
5	kidney development	GO:0001822	10.13	SMAD4 PAX8 MME HNF1B
6	transforming growth factor beta receptor signaling pathway	GO:0007179	10.13	TP53 SMAD4 SMAD3 SMAD2
7	extrinsic apoptotic signaling pathway	GO:0097191	10.1	SMAD3 INHBA IFI27
8	positive regulation of miRNA transcription	GO:1902895	10.09	TP53 SMAD4 SMAD3
9	positive regulation of epithelial to mesenchymal transition	GO:0010718	10.09	SMAD4 SMAD3 SMAD2
10	SMAD protein signal transduction	GO:0060395	9.97	INHBA SMAD2 SMAD3 SMAD4
11	mesoderm formation	GO:0001707	9.95	SMAD3 SMAD2 INHBA
12	regulation of transforming growth factor beta receptor signaling pathway	GO:0017015	9.95	SMAD4 SMAD3 SMAD2
13	adrenal gland development	GO:0030325	9.93	SMAD4 SMAD3 SMAD2
14	pronephros development	GO:0048793	9.9	PAX8 HNF1B
15	positive regulation of follicle-stimulating hormone secretion	GO:0046881	9.89	SMAD4 INHBA
16	developmental growth	GO:0048589	9.89	SMAD4 SMAD3 SMAD2
17	regulation of transforming growth factor beta2 production	GO:0032909	9.84	SMAD4 SMAD3
18	negative regulation of mesenchymal cell apoptotic process involved in metanephros development	GO:1900212	9.81	HNF1B PAX8
19	gastrulation	GO:0007369	9.8	TP53 SMAD4 SMAD3 SMAD2
20	paraxial mesoderm morphogenesis	GO:0048340	9.73	SMAD2 SMAD3
21	SMAD protein complex assembly	GO:0007183	9.73	SMAD4 SMAD3 SMAD2
22	mesonephric tubule development	GO:0072164	9.57	PAX8 HNF1B
23	endoderm development	GO:0007492	9.55	SMAD4 SMAD3 SMAD2 HNF1B
24	regulation of binding	GO:0051098	9.43	SMAD4 SMAD3 SMAD2
25	activin receptor signaling pathway	GO:0032924	9.23	SMAD4 SMAD3 SMAD2 INHBA

Molecular functions related to Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	transcription cis-regulatory region binding	GO:0000976	9.97	TP53 SMAD4 SMAD3 PAX8 HNF1B
2	RNA polymerase II-specific DNA-binding transcription factor binding	GO:0061629	9.85	IFI27 SMAD2 SMAD3 SMAD4 TP53
3	R-SMAD binding	GO:0070412	9.73	SMAD4 SMAD3 SMAD2
4	SMAD binding	GO:0046332	9.67	SMAD4 SMAD3 SMAD2
5	cis-regulatory region sequence-specific DNA binding	GO:0000987	9.5	TP53 SMAD3 SMAD2 HNF1B
6	I-SMAD binding	GO:0070411	9.1	SMAD4 SMAD3 SMAD2